Skip to main content
main-content
Erschienen in: Pneumo News 5/2019

27.08.2019 | Infektionskrankheiten in der Pneumologie | cme fortbildung

Pneumokokken, Pertussis und Influenza

Empfohlene Impfungen bei Lungenkranken

verfasst von: DTMH Hamburg Univ.-Prof. Dr. Florian Thalhammer

Erschienen in: Pneumo News | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Für Lungenkranke ist es wichtig, die Imfungen gegen Grippe, Pneumokokken und Keuchhusten wahrzunehmen, da diese die Morbidität und Mortalität bei invasiven Lungeninfektionen signifikant reduzieren. Eigentlich Grund genug, sich impfen zu lassen — zumindest theoretisch.
Literatur
1.
Zurück zum Zitat Ewig S, Höffken G, Kern WV et al. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention — Update 2016. Pneumologie. 2016 Mar;70(3):151–200 CrossRefPubMed Ewig S, Höffken G, Kern WV et al. Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Prävention — Update 2016. Pneumologie. 2016 Mar;70(3):151–200 CrossRefPubMed
2.
3.
Zurück zum Zitat Adler H, Nikolaou E, Gould K et al. Pneumococcal Colonization in Healthy Adult Research Participants in the Conjugate Vaccine Era, United Kingdom, 2010-2017. J Infect Dis. 2019;219(12):1989–1993 CrossRefPubMedPubMedCentral Adler H, Nikolaou E, Gould K et al. Pneumococcal Colonization in Healthy Adult Research Participants in the Conjugate Vaccine Era, United Kingdom, 2010-2017. J Infect Dis. 2019;219(12):1989–1993 CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Peterson JT, Stacey HL, MacNair JE et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(3):540–548 CrossRefPubMed Peterson JT, Stacey HL, MacNair JE et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(3):540–548 CrossRefPubMed
5.
Zurück zum Zitat Stacey HL, Rosen J, Peterson JT et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15(3):530–539 CrossRefPubMed Stacey HL, Rosen J, Peterson JT et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults. Hum Vaccin Immunother. 2019;15(3):530–539 CrossRefPubMed
6.
Zurück zum Zitat Kolditz M, Schmitt J, Pletz MW, Tesch F. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ?60 years-a population-based retrospective cohort study. Clin Microbiol Infect. 2018;24(5):500–504 CrossRefPubMed Kolditz M, Schmitt J, Pletz MW, Tesch F. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ?60 years-a population-based retrospective cohort study. Clin Microbiol Infect. 2018;24(5):500–504 CrossRefPubMed
7.
Zurück zum Zitat Roca A, Bottomley C, Hill PC et al. Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage. Clin Infect Dis. 2012;55(6):816–24 CrossRefPubMedPubMedCentral Roca A, Bottomley C, Hill PC et al. Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage. Clin Infect Dis. 2012;55(6):816–24 CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010 Jan 1;201(1):32–41 CrossRefPubMed Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010 Jan 1;201(1):32–41 CrossRefPubMed
9.
Zurück zum Zitat van Deursen AMM, van Houten MA, Webber C et al. Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clin Infect Dis. 2017 Sep 1;65(5):787–795 CrossRefPubMed van Deursen AMM, van Houten MA, Webber C et al. Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clin Infect Dis. 2017 Sep 1;65(5):787–795 CrossRefPubMed
10.
Zurück zum Zitat Naucler P, Galanis I, Morfeldt E et al. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clin Infect Dis. 2017;65(11):1780–1789 CrossRefPubMedPubMedCentral Naucler P, Galanis I, Morfeldt E et al. Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations. Clin Infect Dis. 2017;65(11):1780–1789 CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Desmet S, Verhaegen J, Van Ranst M et al. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis. 2018;18(8):830–831 CrossRefPubMed Desmet S, Verhaegen J, Van Ranst M et al. Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defendable approach? Lancet Infect Dis. 2018;18(8):830–831 CrossRefPubMed
12.
Zurück zum Zitat Gessner BD, Sings HL, Jodar L. Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines. Lancet Infect Dis. 2019;19(7):692–693 CrossRefPubMed Gessner BD, Sings HL, Jodar L. Efficacy and effectiveness of ten-valent versus 13-valent pneumococcal conjugate vaccines. Lancet Infect Dis. 2019;19(7):692–693 CrossRefPubMed
13.
Zurück zum Zitat Schroeder MR, Chancey ST, Thomas S et al. A Population-Based Assessment of the Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms. Clin Infect Dis. 2017;65(6):990–998 CrossRefPubMedPubMedCentral Schroeder MR, Chancey ST, Thomas S et al. A Population-Based Assessment of the Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms. Clin Infect Dis. 2017;65(6):990–998 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.https://​doi.​org/​10.​1136/​bmj.​j2471 CrossRefPubMed Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.https://​doi.​org/​10.​1136/​bmj.​j2471 CrossRefPubMed
16.
Zurück zum Zitat van Belkum A, Verkaik NJ, de Vogel CP et al. Reclassification of Staphylococcus aureus nasal carriage types. J Infect Dis. 2009;199(12):1820–6 CrossRefPubMed van Belkum A, Verkaik NJ, de Vogel CP et al. Reclassification of Staphylococcus aureus nasal carriage types. J Infect Dis. 2009;199(12):1820–6 CrossRefPubMed
17.
Zurück zum Zitat Schauwvlieghe AFAD, Rijnders BJA, Philips N et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782–792 CrossRefPubMed Schauwvlieghe AFAD, Rijnders BJA, Philips N et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782–792 CrossRefPubMed
18.
Zurück zum Zitat Kwong JC, Schwartz KL, Campitelli M et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345–353 CrossRefPubMed Kwong JC, Schwartz KL, Campitelli M et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345–353 CrossRefPubMed
19.
Zurück zum Zitat Modin D, Jørgensen ME, Gislason G et al. Influenza Vaccine in Heart Failure. Circulation. 2019;139(5):575–586 CrossRefPubMed Modin D, Jørgensen ME, Gislason G et al. Influenza Vaccine in Heart Failure. Circulation. 2019;139(5):575–586 CrossRefPubMed
20.
Zurück zum Zitat Lee KR, Bae JH, Hwang IC et al. Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2017;48(3–4):103–110 CrossRef Lee KR, Bae JH, Hwang IC et al. Effect of Influenza Vaccination on Risk of Stroke: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2017;48(3–4):103–110 CrossRef
21.
Zurück zum Zitat Fukuta H, Goto T, Wakami K et al. The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2019;24(1):109–114 CrossRefPubMed Fukuta H, Goto T, Wakami K et al. The effect of influenza vaccination on mortality and hospitalization in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2019;24(1):109–114 CrossRefPubMed
22.
Zurück zum Zitat Vasileiou E, Sheikh A, Butler C et al. Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2017;65(8):1388–1395 CrossRefPubMedPubMedCentral Vasileiou E, Sheikh A, Butler C et al. Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2017;65(8):1388–1395 CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Evans GM, Gaisford WF. Treatment of Pneumonia with 2-(p-aminobenzenesulphonamido) pyridine. Lancet. 1938;232(5992):14–19 CrossRef Evans GM, Gaisford WF. Treatment of Pneumonia with 2-(p-aminobenzenesulphonamido) pyridine. Lancet. 1938;232(5992):14–19 CrossRef
25.
Zurück zum Zitat Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort. Am J Respir Crit Care Med. 2015;192(5):597–604 CrossRefPubMed Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Ten-Year Mortality after Community-acquired Pneumonia. A Prospective Cohort. Am J Respir Crit Care Med. 2015;192(5):597–604 CrossRefPubMed
26.
Zurück zum Zitat Barker WH, Mullooly JP. A study of excess mortality during influenza epidemics in the United States, 1968–1976. Am J Epidemiol. 1982;115(3):479–80 CrossRefPubMed Barker WH, Mullooly JP. A study of excess mortality during influenza epidemics in the United States, 1968–1976. Am J Epidemiol. 1982;115(3):479–80 CrossRefPubMed
28.
Zurück zum Zitat Schmitzberger, MEDahead Experten Statement 2017 Schmitzberger, MEDahead Experten Statement 2017
29.
Zurück zum Zitat CDC Advisory Committee on Immunization Practices (ACIP) Meeting, Juni 2018 CDC Advisory Committee on Immunization Practices (ACIP) Meeting, Juni 2018
31.
Zurück zum Zitat Gesundheitsministerium, Österreichische Ärztekammer, Östereichische Apothekerkammer Gesundheitsministerium, Österreichische Ärztekammer, Östereichische Apothekerkammer
Metadaten
Titel
Pneumokokken, Pertussis und Influenza
Empfohlene Impfungen bei Lungenkranken
verfasst von
DTMH Hamburg Univ.-Prof. Dr. Florian Thalhammer
Publikationsdatum
27.08.2019
Verlag
Springer Medizin
Erschienen in
Pneumo News / Ausgabe 5/2019
Print ISSN: 1865-5467
Elektronische ISSN: 2199-3866
DOI
https://doi.org/10.1007/s15033-019-1231-9

Weitere Artikel der Ausgabe 5/2019

Pneumo News 5/2019 Zur Ausgabe